Proportion of women who have commenced ART by beginning of week 24 of pregnancy. Proportion of women with a baseline HIV VL >30 000 RNA copies/mL selleck products plasma and who do not require treatment

for themselves commencing temporary HAART at the beginning of the second trimester (by beginning of 16 weeks’ gestation). Proportion of women presenting in labour/with ROM/requiring delivery without a documented HIV result having an urgent HIV test result documented and this reactive/positive result acted upon immediately with initiation of the interventions to PMTCT without waiting for further/formal serological confirmation. Proportion of women with HBV coinfection who have LFTs performed 2 weeks after commencing HAART to detect evidence of ARV hepatotoxicity or IRIS. Proportion of women with HCV coinfection who have LFTs performed 2 weeks after commencing HAART to detect evidence of ARV hepatotoxicity or IRIS. Proportion of women

who have invasive prenatal diagnostic testing performed before their HIV status is known. Proportion of emergency CS performed and their indication. Proportion of infants <72 h old, born to untreated HIV-positive mothers, initiating three-drug therapy within 2 h of delivery. Proportion of routine neonatal PEP commenced within 4 h of delivery. Proportion of infants born to HIV-positive mothers who have HIV antibody testing for seroreversion performed at age 15–24 months. One of Everolimus the major successes in the management of HIV-positive patients has been the PMTCT of HIV-1. With the widespread implementation of routine antenatal screening Nintedanib in vitro for HIV-1, transmission of HIV-1 from mother to child is now a rare occurrence in the UK. Despite few recent RCTs regarding the use of ART in pregnancy or obstetric intervention, practice continues to evolve. This is largely informed by observational data, theoretical considerations and expert

opinion. At the outset, the aim of the Writing Group was to make these guidelines as clinically relevant and as practical as possible. The Writing Group drew up a list of questions reflecting day-to-day practice and queries. It was acknowledged that the level of evidence for many of these topics was poor but recognized that there was a need to provide guidance. These guidelines have expanded on all areas relevant to the clinical care of HIV-positive pregnant women. The guidelines are intended to inform and aid healthcare workers in the management of pregnant women with HIV. They are not intended to be prescriptive or restrictive and it is recognized that situations will arise where the optimum management may deviate from these recommendations and new data will emerge to better inform practice. A particular focus has been obstetric management. An increasing number of women are aiming for and achieving a vaginal delivery but the rate of emergency CSs has increased.